TC

30/09/2020 11:16

CStone Pharma (02616) to cooperate with Pfizer

   CStone Pharmaceuticals (02616) said it has entered into a share subscription agreement with Pfizer Corporation. Pfizer Corporation has conditionally agreed to subscribe for the subscription shares at the subscription price of approximately HK$13.37 per share.
  The subscription shares represent 9.9% of the issued share capital of the company as enlarged. The gross proceeds will be approximately US$200 million, which will be used for the funding of the development activities under the collaboration agreement.
  The group has also entered into a collaboration agreement with Pfizer Investment. The Group and Pfizer Investment have agreed to enter into a strategic collaboration primarily in relation to (i) the CS1001 collaboration, whereby the group has agreed to grant Pfizer Investment an exclusive licence to commercialize CS1001, an anti-PD-L1 monoclonal antibody of the company, in the PRC; the additional asset collaboration, whereby the parties have agreed to collaborate on the development and commercialization of the additional assets in the collaborative territory; and (iii) the in-licensed asset collaboration, whereby the parties have agreed to collaborate to jointly acquire or in-license the in-licensed assets and develop and commercialize such in-licensed assets in the collaborative territory.

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【嚴正聲明】《經濟通》呼籲公眾提高警覺留意偽冒《經濟通》投資群組

如何分辨問米是否真實?通靈問事用什麼工具都可以?靈靈法即場示範通靈!

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

Watche Trends 2024

北上食買玩

Art Month 2024

理財秘笈

夏天養生食療

消委會報告

山今養生智慧

輕鬆護老